2009.7000 -0.90 (-0.04%)
NSE Dec 29, 2025 15:31 PM
Volume: 267.0K
 

2009.70
-0.04%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
More from Glenmark Pharmaceuticals Ltd.
Recommended